Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Encequidar

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Athenex Provides Update Regarding Oral Paclitaxel Plus Encequidar
    Athenex Provides Update Regarding Oral Paclitaxel Plus Encequidar

    06 Jul 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/07/06/2258065/0/en/Athenex-Provides-Update-from-FDA-Type-A-Meeting-Regarding-Oral-Paclitaxel-Plus-Encequidar-for-the-Treatment-of-Metastatic-Breast-Cancer.html

    GLOBENEWSWIRE
    06 Jul 2021
    Share Share
    Athenex Presents Updated Phase 3 Data on Survival & Tolerability Oral Paclitaxel
    Athenex Presents Updated Phase 3 Data on Survival & Tolerability Oral Paclitaxel

    09 Dec 2020

    // PRESS RELEASE

    https://ir.athenex.com/news-releases/news-release-details/athenex-presents-updated-phase-3-data-survival-and-tolerability#:~:text=December%209%2C%202020-,Athenex%20Presents%20Updated%20Phase%203%20Data%20on%20Survival%20and%20Tolerability,Patients%20with%20Metastatic%20Breast%20Cancer&text=OS%20versus%20IVP.-,Oral%20paclitaxel%20demonstrated%20a%20median%20PFS%20of%208.4%20months%20vs,OS%20of%2023.3%20months%20vs.

    PRESS RELEASE
    09 Dec 2020
    Share Share
    Athenex Up 13% As FDA Grants Priority Review For NDA Of Breast Cancer Drug
    Athenex Up 13% As FDA Grants Priority Review For NDA Of Breast Cancer Drug

    01 Sep 2020

    // NASDAQ

    https://www.nasdaq.com/articles/stock-alert%3A-athenex-up-13-as-fda-grants-priority-review-for-nda-of-breast-cancer-drug

    NASDAQ
    01 Sep 2020
    Share Share
    Athenex Announces FDA Acceptance for Oral Paclitaxel and Encequidar
    Athenex Announces FDA Acceptance for Oral Paclitaxel and Encequidar

    01 Sep 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/09/01/2086762/0/en/Athenex-Announces-FDA-Acceptance-for-Filing-of-U-S-NDA-for-Oral-Paclitaxel-and-Encequidar-in-Metastatic-Breast-Cancer-with-Priority-Review.html

    GLOBENEWSWIRE
    01 Sep 2020
    Share Share